Aurobindo Shares Soar 4% as USFDA Classifies Facility as VAI
Shares of Aurobindo Pharma Ltd soared roughly 4% on Wednesday, 6 May, after the company said that the US Food and Drug Administration (USFDA) has classified its Unit-VII facility in Telangana as “Voluntary Action Indicated” (VAI). The factory, which produces oral solid dosage products, is located at the Special Economic... The post Aurobindo Shares Soar 4% as USFDA Classifies Facility as VAI appeared first on Equitypandit.
Shares of Aurobindo Pharma Ltd soared roughly 4% on Wednesday, 6 May, after the company said that the US Food and Drug Administration (USFDA) has classified its Unit-VII facility in Telangana as “Voluntary Action Indicated” (VAI).
The factory, which produces oral solid dosage products, is located at the Special Economic Zone (Pharma), TSIIC, Green Industrial Park in Polepally Village, Jedcherla Mandal, Telangana.
The USFDA inspected the plant from 28 January to 10 February 2026. At the conclusion of the inspection, the regulator issued Form 483 with nine observations.
In an exchange filing, Aurobindo Pharma stated that it has now received the Establishment Inspection Report (EIR) categorising the facility as VAI, and that the USFDA has completed the inspection and closed the case.
A VAI rating means that, while undesirable conditions were discovered during the inspection, the regulator does not recommend or take any administrative or regulatory action at the institution.
Earlier, in April, Aurobindo Pharma’s subsidiary, TheraNym Biologics Pvt Ltd, increased its relationship with Merck Sharpe & Dohme Singapore Trading Pte Ltd (MSD) by signing an additional product schedule under their existing contract manufacturing (CMO) arrangement, which runs until May 2024.
According to the new agreement, TheraNym Biologics will establish a greenfield facility for large-scale mammalian drug substance synthesis (Unit 2) with a total bioreactor capacity of 60 KL. The corporation intends to invest between $150 and $175 million to develop this plant.
At 12:41 pm, the shares of Aurobindo Pharma were trading 3.55% higher at Rs 1,478.80 on NSE.
Ready to invest like a pro? Tradz by EquityPandit app equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz by EquityPandit app and gain access to daily stock lists and insightful market analysis and much more!
The post Aurobindo Shares Soar 4% as USFDA Classifies Facility as VAI appeared first on Equitypandit.
What's Your Reaction?
